The new STAAR EVO Experience Center.

  
LAKE FOREST, Calif.—STAAR Surgical Company, a leading developer, manufacturer and marketer of implantable lenses for the eye, announced the opening of the first company-operated EVO Experience Center at its corporate headquarters in Lake Forest, Calif. EVO ICL and EVO+ ICL are STAAR Surgical's phakic IOLs for myopia and astigmatism. Made from collamer, EVO ICL (Evolution in Visual Freedom) can treat a wide range of refractive error, according to STAAR Surgical. The lens is approved by the FDA.

“We are very excited to open the first company-operated EVO Experience Center for ophthalmic healthcare practitioners which is designed to provide an immersive lens-based education experience with all the necessary tools, assets and resources to grow a successful EVO practice,” said Caren Mason, president and CEO of STAAR Surgical.

“Similar EVO training centers already exist in hospitals, clinics and universities outside the U.S. and we are delighted to establish the first EVO Experience Center in the U.S. at our corporate headquarters. STAAR is committed to the comprehensive sharing of EVO ICL best practices, training, education and practice development.
 
“We anticipate that our EVO Experience Center will elevate interest, training and adoption of EVO ICL, globally, among existing and potential EVO ophthalmic surgeons and healthcare practitioners.”
 
 
 Eyecare professionals try out the educational tools at the opening of the STAAR EVO Experience Center.
  
The EVO Experience Center is equipped with advanced visualization and communications technology, allowing for in-person and virtual training, medical education and practice development programs. The center features a surgical simulation room along with meeting spaces that will showcase STAAR’s global consumer marketing, and include practice development tools for interactive discussion. 
 
The center officially opened on November 10, 2022, with a grand opening event attended by local ophthalmic surgeons and staff, STAAR management and clinical staff, and EVO patients.